RecruitingPhase 2NCT07040566

A Trial of Varenicline for E-cigarette Cessation

Investigating Efficacious E-Cigarette Interventions and Cessation Effects on Cancer-Related Biomarkers: A Randomized Trial of Varenicline in Adults

Sponsor

Yale University

Enrollment

326 participants

Start Date

Oct 14, 2025

Study Type

INTERVENTIONAL

Conditions

Vaping E-cigarette use Nicotine Dependence

Summary

This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Varenicline 1mg BID for people with e-cigarette use, nicotine dependence, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.